Buy Liothyronine Sodium T3
Related Keywords: Loyd V. Allen, Jr., PhD, RPh, liothyronine sodium, T3, transdermal administration, topical preparations, hypothyroidism, thyroid disorders, thyroid hormone replacement, formulation, functional hypometablism
buy liothyronine sodium t3
ABOUT T3 (LIOTHYRONINE SODIUM): Liothyronine Sodium is the salt form of liothyronine. It is a synthetic form of the naturally occurring thyroid hormone, triiodothyronine (T3). Liothyronine sodium binds to nuclear thyroid receptors. Consequently, liothyronine sodium induces gene expression that is necessary for growth and development. Liothyronine sodium is more potent than thyroxine (T4).
Liothyronine sodium is almost completely absorbed from the gastrointestinal tract, about 95% following oral administration. It may be useful in restoring TH signaling in hypothyroid laboratory animals. Adding it to the drinking water or food avoids the administration of a single dose of LT3 restores thyroid status in thyroidectomized rodents.
Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. T4 contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT). T3 contains three atoms of iodine and is formed by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hormones are stored in the thyroid colloid as thyroglobulin.
Each round, white to off-white Cytomel (liothyronine sodium) tablet contains liothyronine sodium equivalent to liothyronine as follows: 5 mcg debossed KPI and 115; 25 mcg scored and debossed KPI and 116; 50 mcg scored and debossed KPI and 117. Inactive ingredients consist of calcium sulfate, gelatin, corn starch, stearic acid, sucrose and talc.
Cytomel (liothyronine sodium) Tablets are intended fororal administration; once-a-day dosage is recommended. Although liothyroninesodium has a rapid cutoff, its metabolic effects persist for a few daysfollowing discontinuance.
The rapid onset and dissipation of action of liothyroninesodium (T3), as compared with levothyroxine sodium (T4), has led someclinicians to prefer its use in patients who might be more susceptible to the untowardeffects of thyroid medication. However, the wide swings in serum T levels thatfollow its administration and the possibility of more pronounced cardiovascularside effects tend to counterbalance the stated advantages.
Cytomel (liothyronine sodium) Tablets may be used inpreference to levothyroxine (T4) during radioisotope scanning procedures, sinceinduction of hypothyroidism in those cases is more abrupt and can be of shorterduration. It may also be preferred when impairment of peripheral conversion ofT4 to T3 is suspected.
When switching a patient to Cytomel (liothyronine sodium)Tablets from thyroid, L-thyroxine or thyroglobulin, discontinue the othermedication, initiate Cytomel at a low dosage, and increase gradually accordingto the patient's response. When selecting a starting dosage, bear in mind thatthis drug has a rapid onset of action, and that residual effects of the otherthyroid preparation may persist for the first several weeks of therapy.
Cytomel (liothyronine sodium) Tablets are given in dosesof 75 to 100 mcg/day for 7 days, and radioactive iodine uptake is determinedbefore and after administration of the hormone. If thyroid function is undernormal control, the radioiodine uptake will drop significantly after treatment.Cytomel (liothyronine sodium) Tablets should be administered cautiously topatients in whom there is a strong suspicion of thyroid gland autonomy, in viewof the fact that the exogenous hormone effects will be additive to theendogenous source.
Adverse reactions, other than those indicative ofhyperthyroidism because of therapeutic overdosage, either initially or duringthe maintenance period are rare (see OVERDOSAGE). In rare instances,allergic skin reactions have been reported with Cytomel (liothyronine sodium) Tablets.
Thyroid hormones should be used with great caution in anumber of circumstances where the integrity of the cardiovascular system,particularly the coronary arteries, is suspected. These include patients withangina pectoris or the elderly, in whom there is a greater likelihood of occultcardiac disease. In these patients, liothyronine sodium therapy should beinitiated with low doses, with due consideration for its relatively rapid onsetof action. Starting dosage of Cytomel (liothyronine sodium) Tablets is 5 mcgdaily, and should be increased by no more than 5 mcg increments at 2-weekintervals. When, in such patients, a euthyroid state can only be reached at theexpense of an aggravation of the cardiovascular disease, thyroid hormone dosageshould be reduced.
Treatment of patients with thyroid hormones requires theperiodic assessment of thyroid status by means of appropriate laboratory testsbesides the full clinical evaluation. The TSH suppression test can be used totest the effectiveness of any thyroid preparation, bearing in mind the relativeinsensitivity of the infant pituitary to the negative feedback effect ofthyroid hormones. Serum T4 levels can be used to test the effectiveness of allthyroid medications except products containing liothyronine sodium. When the totalserum T4 is low but TSH is normal, a test specific to assess unbound (free) T4levels is warranted. Specific measurements of T4 and T3 by competitive proteinbinding or radioimmunoassay are not influenced by blood levels of organic orinorganic iodine and have essentially replaced older tests of thyroid hormonemeasurements, i.e., PBI, BEI and T4 by column.
Clinical studies of liothyronine sodium did not includesufficient numbers of subjects aged 65 and over to determine whether theyrespond differently from younger subjects. Other reported clinical experiencehas not identified differences in responses between the elderly and youngerpatients. In general, dose selection for an elderly patient should be cautious,usually starting at the low end of the dosing range, reflecting the greaterfrequency of decreased hepatic, renal, or cardiac function, and of concomitantdisease or other drug therapy. This drug is known to be substantially excretedby the kidney, and the risk of toxic reactions to this drug may be greater inpatients with impaired renal function. Because elderly patients are more likelyto have decreased renal function, care should be taken in dose selection, andit may be useful to monitor renal function.
Since liothyronine sodium (T3) is not firmly bound toserum protein, it is readily available to body tissues. The onset of activityof liothyronine sodium is rapid, occurring within a few hours. Maximum harmacologicresponse occurs within 2 or 3 days, providing early clinical response. Thebiological half-life is about 2- days.
Each mL of liothyronine sodium injection (T3) in amber glass vials contains, in sterile non-pyrogenic aqueous solution, liothyronine sodium equivalent to 10 mcg of liothyronine; alcohol, 6.8% by volume; anhydrous citric acid, 0.175 mg; ammonia, 2.19 mg, as ammonium hydroxide; Water for injection, USP.
Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. T4 contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT). T3 contains three atoms of iodine and is formed by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hormones are stored in the thyroid colloid as thyroglobulin and released into the circulation. The major source of T3 has been shown to be peripheral deiodination of T4. T3 is bound less firmly than T4 in the serum, enters peripheral tissues more readily, and binds to specific nuclear receptor(s) to initiate hormonal, metabolic effects. T4 is the prohormone which is deiodinated to T3 for hormone activity.
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of liothyronine in children. Recommended doses should not be exceeded, and the patient should be carefully monitored during treatment.
Appropriate studies performed to date have not demonstrated geriatrics-specific problems that would limit the usefulness of liothyronine in the elderly. However, elderly patients are more likely to have age-related kidney or heart or blood vessel problems, which may require caution and an adjustment in the dose for patients receiving liothyronine.
If you use medicine to treat high cholesterol (including cholestyramine, colesevelam, colestipol), Kayexalate, or sevelamer, take liothyronine at least 4 hours before you take any of these medicines.
Certain medications can decrease the absorption of liothyronine. Examples include products that contain aluminum or magnesium, antacids, sucralfate, calcium supplements, iron, bile acid-binding resins (such as cholestyramine, colestipol, colesevelam), simethicone, sevelamer, sodium polystyrene sulfonate, among others. If you take any of these medications, take them at least 4 hours before or after liothyronine. If you take lanthanum, take it at least 2 hours before or after liothyronine.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345. Precautions Before taking liothyronine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company. Images liothyronine 50 mcg tablet 041b061a72